Skip to main content
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2013 Apr 23;4:40. doi: 10.3389/fphar.2013.00040

Genetic Influences on Cystic Fibrosis Lung Disease Severity

Colleen A Weiler 1, Mitchell L Drumm 1,2,*
PMCID: PMC3632778  PMID: 23630497

Abstract

Understanding the causes of variation in clinical manifestations of disease should allow for design of new or improved therapeutic strategies to treat the disease. If variation is caused by genetic differences between individuals, identifying the genes involved should present therapeutic targets, either in the proteins encoded by those genes or the pathways in which they function. The technology to identify and genotype the millions of variants present in the human genome has evolved rapidly over the past two decades. Originally only a small number of polymorphisms in a small number of subjects could be studied realistically, but speed and scope have increased nearly as dramatically as cost has decreased, making it feasible to determine genotypes of hundreds of thousands of polymorphisms in thousands of subjects. The use of such genetic technology has been applied to cystic fibrosis (CF) to identify genetic variation that alters the outcome of this single gene disorder. Candidate gene strategies to identify these variants, referred to as “modifier genes,” has yielded several genes that act in pathways known to be important in CF and for these the clinical implications are relatively clear. More recently, whole-genome surveys that probe hundreds of thousands of variants have been carried out and have identified genes and chromosomal regions for which a role in CF is not at all clear. Identification of these genes is exciting, as it provides the possibility for new areas of therapeutic development.

Keywords: polymorphism, genotype, phenotype

Cystic Fibrosis Background

Cystic fibrosis (CF) is the most common lethal autosomal recessive disease in Caucasians, affecting an estimated 1 in 3,300 live-born infants (Davis et al., 1996). Affected individuals have variants in both copies of the 230-kb CF transmembrane conductance regulator gene (CFTR), that result in significant reduction or absence of CFTR function. The CFTR gene is located on the long arm of chromosome 7 at position 7q31and encodes a 1,480 amino acid protein (Riordan et al., 1989; Rommens et al., 1989) with cAMP-dependent anion channel activity (Bear et al., 1992) found in the apical membranes of epithelial cells in the lungs, olfactory sinuses, pancreas, intestines, vas deferens, and sweat ducts, as well as non-epithelial cells such as immune cells (myeloid and lymphocytes) and various muscle cell types (Yoshimura et al., 1991; Krauss et al., 1992; McDonald et al., 1992; Dong et al., 1995; Moss et al., 2000; Robert et al., 2005; Di et al., 2006; Vandebrouck et al., 2006; Divangahi et al., 2009; Lamhonwah et al., 2010). Low or absent CFTR function in the airway epithelium not only results in decreased chloride permeability, but also in increased sodium absorption across the epithelium, impairing hydration of the airway mucosal surface and resulting in thick, sticky mucus and an environment for bacteria to thrive. Thus, typical clinical features of CF include chronic infection and inflammation of the airways. Accordingly, a hallmark characteristic of the CF airways is progressive bronchiectasis; this destruction and dilation of the airways is the primary cause of morbidity and mortality of CF patients. In addition to the airway manifestations, most CF patients will experience exocrine pancreatic insufficiency, males are most often sterile, and other co-morbidities such as liver disease and diabetes are common as well. Previously considered almost exclusively a pediatric disease, CF babies now have a predicted median survival of nearly 40 years (Cystic Fibrosis Foundation Patient Registry, 2009).

Heterogeneity of CFTR

To date, over 1,800 CF-associated mutations have been described1 and the effects of these mutations have been grouped into six general classes based on the consequence to CFTR message and/or protein (Zielenski, 2000). These range from complete absence of full-length, functional CFTR protein (class I), proteins that do not traffic to the membrane well due to misfolding (class II), proteins that reach the membrane but do not respond to activation stimuli such as phosphorylation (class III), proteins that reach the membrane and activate, but do not conduct anions sufficiently to prevent disease (class IV), mutations that reduce the amount of functional CFTR, such as by gene expression regulation or protein trafficking (class V), and proteins that are unstable and experience increased turnover in the plasma membrane (class VI). It should be noted that these classes are not mutually exclusive, as a single change may have multiple effects on the protein.

Given the diversity of mutations, it is perhaps not surprising that there is a wide range of phenotypic variability in CF simply due to variation in CFTR. Many reports of correlations between CFTR genotype and clinical phenotype exist (Kerem et al., 1990a; Stuhrmann et al., 1991; The Cystic Fibrosis Genotype-Phenotype Consortium, 1993; Tsui and Durie, 1997; Zielenski, 2000), with the most extensive catalog to date carried out as an international effort2 and currently includes data on over 35,000 patients. Because most CF mutations are rare, surveying such a large number of individuals makes it possible to most reliably assess the phenotypic effects associated with a genotype, rather than extrapolate from individual cases.

In addition to CFTR genotype, there is evidence that gender contributes to phenotypic variability (Davis, 1999). Females are reported to have a reduced median survival age (by approximately 3 years), an earlier average age of Pseudomonas aeruginosa infection in the lungs, greater rates of pulmonary decline, and elevated resting energy expenditure when compared to males (Demko et al., 1995; Corey et al., 1997; Allen et al., 2003). Although some current studies replicate these findings (Barr et al., 2011; Reid et al., 2011), others show no evidence of a gender gap and propose that phenotypic variability could be attributed to non-uniformity of care or the need to account for other factors such as body habitus, presence of diabetes, or the finding that females are more likely to be diagnosed later in life than males (Widerman et al., 2000; Milla et al., 2005; Rodman et al., 2005; Verma et al., 2005; Stern et al., 2008; Fogarty et al., 2012).

Genomic Heterogeneity and Clinical Variation

Even among patients with the same CFTR genotype, there is a wide range of phenotypic variability (Kerem et al., 1990a; Tsui and Durie, 1997). Perhaps most notably, there is remarkable variation of pulmonary phenotype, with some patients maintaining normal lung function well into adolescence and adulthood while others do quite poorly even at a very young age (Kerem et al., 1990a). Understanding the causes of this variation is important, as it provides insight into developing new therapies, or improving existing ones.

Clearly environmental factors contribute to clinical variation; exposure to tobacco smoke, bacterial infections, and socioeconomic status have all been implicated as having detrimental effects on pulmonary phenotype of CF patients (Kerem et al., 1990b; Rubin, 1990; Corey and Farewell, 1996; Schechter et al., 2001; O’Connor et al., 2003) while improvement of nutritional status, through aggressive treatment, has been associated with improvements in pulmonary phenotype (Steinkamp and von der Hardt, 1994). Each of the environmental sources of clinical variation provide potential intervention points, but it is also clear that there are heritable sources (Mekus et al., 2000; Vanscoy et al., 2007) of variation as well and that may provide insight into even more therapeutic targets.

Evidence of Genetic Modifiers of Disease

Human twin and sibling studies have been useful in verifying the role of modifier genes, and quantifying their contribution to phenotypic variation. Mekus et al. (2000) found in a survey of 277 sibling pairs, with 29 monozygous and 12 dizygous pairs, that a combined index of lung function and body mass was more concordant among monozygous twins (sharing 100% of genetic material) than dizygous twins or other sibling pairs (sharing 50% of genetic material), pointing to a genetic etiology of variation. Similarly, Vanscoy et al. (2007) examined the pulmonary phenotype of 57 twin pairs and 231 sibling pairs with CF. Lung function measurements were significantly more concordant between monozygous twins than dizygous twins, also indicating the presence of genetic modifiers. The similarity in lung function between sibling pairs was compared to the similarity in lung function in unrelated patients, and again was found to be more similar. Heritability estimates were calculated from these data, and it was determined that non-CFTR genetic variation could account for approximately 50–80% of the pulmonary phenotypic variability in CF patients with the same CFTR genotype (homozygous F508del) (Vanscoy et al., 2007).

Genetic Approaches

With a genetic component established, the next task at hand was to identify the genes responsible. There are two fundamental strategies by which to accomplish this. One requires family information and is often referred to as linkage analysis. Through this approach, one determines whether a polymorphism’s genotype is concordant in siblings with similar clinical profiles, discordant when clinical features are discordant or show no pattern. The other approach is association, determining if particular alleles of a polymorphism are distributed randomly among patients or have skewed distributions that track with clinical characteristics. These two approaches are outlined in Figure 1 and the findings that these strategies have produced are listed in Table 1 with several examples described in more detail below.

Figure 1.

Figure 1

Linkage analysis tracks alleles of polymorphisms through families to determine if an allele is linked to a phenotype. In this example, alleles of gene 1, 1A, 1B, 1C, and 1D, track with severity (black, severe; gray, mild), showing concordant genotypes between siblings with similar phenotypes (left pedigree) and discordant genotypes when phenotypes are dissimilar (right pedigree). In contrast, genotype and phenotype show no relationship at polymorphism 2. Association studies examine a population of unrelated individuals to determine if particular alleles of a polymorphism are found in different proportions, depending on the disease profile. In the example here, alleles 1A and 1B have equal frequencies in the population, but 1A is much higher in the severely affected subjects (black) and 1B higher in the mildly affected subset (gray).

Table 1.

Summary of published cystic fibrosis pulmonary modifiers.

Gene/locus Genes involved Variant aliases Variant position (rs no.) Phenotypes tested Association p-value Source n (reference) Replication n (reference) Tested, not replicated n (reference)
8.1AH LTA
TNF
+252 A > G
−308 G > A
909253
1800629
FEV1 % pred
Chronic P. aeruginosa
colonization
<0.04
0.99
404 (Corvol et al., 2012)
HSP70-2
RAGE
1267 A > G
−429 T > C
106158
1800625
8.1MHC AGER
HSP70-2
−429 T > C
1267 A > G
106158 Age at onset of colonization Frequency of colonization 0.036
0.012
72 (Laki et al., 2006)
TNFA G-308A
11p13 APIP
EHF
12793173 FEV1 % pred (adjusted) 3.34 × 10−8 1,978 (Wright et al., 2011) 557 (Wright et al., 2011)
19q13 hCFM1 APOC2, D19S219, D19S112 haplotype FEV1 % pred 0.779 197 sib pairs (Zielenski et al., 1999)
A1AT SERPINA1 1237 G > A 11568814 FEV1 % pred CXR score Age at onset of P. aeruginosa 0.368
0.813
0.146
157 (Mahadeva et al., 1998b) 716 (Frangolias et al., 2003) 124 (Henry et al., 2001) 320(Courtney et al., 2006) 808 (Drumm et al., 2005)
S allele Z allele 17580
28929474
FEV1% pred CXR score Age at onset of P. aeruginosa 0.043
0.127
0.899
157 (Mahadeva et al., 1998b) 215 (Doring et al., 1994) 79 (Mahadeva et al., 1998a) 124 (Henry et al., 2001) 269 (Meyer et al., 2002) 808 (Drumm et al., 2005)
ABCC1 MRP-1 4741 C > G 504348 Age at onset of P. aeruginosa Age at which FEV1 < 60% 0.0644
<0.05
203 (Mafficini et al., 2011)
FEV1 % pred 0.52
ABO T99T
21404 C > A
8176719
8176720
1053878
Pulmonary disease severity Age at onset of P. aeruginosa No association No association 778 (Taylor-Cousar et al., 2009)
R176G 7853989
21583 T > A 8176740
H219H 8176741
P227P 8176742
816750
66119 G > A 8176472
ACE Insertion or deletion Age of first P. aeruginosa infection 0.9 261 (Arkwright et al., 2003) 808 (Drumm et al., 2005)
Age at which FEV1 < 50% 0.03 (0.04)§
Age of death No association
ADRB2 Arg16Gly 1042713 FEV1 % pred FVC <0.05
<0.05
126 (Buscher et al., 2002) 808 (Drumm et al., 2005)
Flows at lower lung volumes <0.01
5 year decline in pulmonary function <0.01
Gln27Glu
Thr164Ile
1042714
1800888
Bronchodilator responses to albuterol NS
Pulmonary function Reduced
AGER −429T > C 1800625 FEV1 Kulich CF-specific percentile z-score 0.02
0.03
967 (Beucher et al., 2012)
KNoRMA 0.03
AGTR2 1403543 FEV1 % pred (adjusted) 1.61 × 10−5 1,978 (Wright et al., 2011) 557 (Wright et al., 2011)
AHRR 12188164 FEV1% pred (adjusted) 5.92 × 10−4 1,978 (Wright et al., 2011) 557 (Wright et al., 2011)
C3 31778 G > A 393770 FEV1 % pred 0.75 (0.05) 755 (Park et al., 2011)
4023 T > G 11569393 0.66 (0.03)
39718 G > A 7257062 0.78 (0.52)
CD14 −159 C > T Pulmonary disease severity No association 105 (Faria et al., 2009)
CDH8 11645366 FEV1 % pred (adjusted) 1.23 × 10−5 1,978 (Wright et al., 2011) 557 (Wright et al., 2011)
CEACAM3 19q13 6508999–10414823 Disease severity 0.0469 37 nuclear families (Stanke et al., 2010)
CEACAM6 19q13 1549960–11548735 Disease severity 0.0106 37 nuclear families (Stanke et al., 2010)
CFB 7680 A > G 537160 FEV1 % pred 0.50 (0.83) 755 (Park et al., 2011)
10858 A > G 2072633 0.68 (0.74)
CLCN2 CLC-2 −693 A > G FEV1 % pred 0.72 74 (Blaisdell et al., 2004)
358 G > C 0.32
427 A > G 0.32
1089 T > C 0.21
1909 G > C 0.22
DCTN4 Any missense variant 11954652 Age at onset of chronic P. aeruginosa infection 0.05
0.002
91 (Emond et al., 2012)
35772018 Age of first P. aeruginosa infection 0.01 645 (Emond et al., 2012)
Age at onset of chronic P. aeruginosa infection 0.004 530
Age at onset of mucoid P. aeruginosa infection 0.03
Time from first detection of P. aeruginosa infection to mucoid P. aeruginosa 0.01
DEFB1 Frequent polymorphisms Age of first P. aeruginosa infection No association 210 (Vankeerberghen et al., 2005) 62 (Segat et al., 2010) 224 (Tesse et al., 2008) 92 (Crovella et al., 2011)+
FEV1% No association
DEFB4 Genomic copy number (2–12) of repeat unit Pulmonary disease (mean and current FEV1, mean and current FVC) No association 355 (Hollox et al., 2005)
EDNRA 6672 G > C 5335 Pulmonary function (FEV1) 0.002 1,577 (Darrah et al., 2010)
EEA1 4760506 FEV1 % pred (adjusted) 6.77 × 10−6 1,978 (Wright et al., 2011) 557 (Wright et al., 2011)
FCGR2 FcγRII R131H Chronic P. aeruginosa colonization 0.042 167 (De Rose et al., 2005)
FUT2 G428A 601338 Impairment of lung function (FEV1) 0.569 806 (Taylor-Cousar et al., 2009)
FUT3 T59G 28362459 Impairment of lung function (FEV1) 0.544 707 (Taylor-Cousar et al., 2009)
T202C 812936 0.491
C314T 778986 0.615
T1067A 3894326 0.792
GCLC (GAG)n FEV1 % pred 0.097 440 (McKone et al., 2006)
0.001 (mild)
0.533 (severe)
GSTM1 GSTM1*0/
GSTM1*0
FEV1 % pred 0.16 53 (Hull and Thomson, 1998) 194 (Baranov et al., 1996) 146 (Flamant et al., 2004)
Chrispin–Norman score 0.02 808 (Drumm et al., 2005)
Shwachman score 0.04 60 (Korytina et al., 2004)
Positive for P. aeruginosa 0.12
No. of ΔF508 homozygotes 0.43
GSTM3 GSTM3*A 1799735 FEV1 0.01 146 (Flamant et al., 2004)
GSTM3*B FVC 0.002
GSTP1 1375 A > G 947894 Spirometry NS 146 (Flamant et al., 2004) 808 (Drumm et al., 2005) 60 (Korytina et al., 2004)
I105V
GSTT1 GSTT1*0/ Spirometry NS 146 (Flamant et al., 2004)
GSTT1*0
HFE C282Y and/or
H63D
1800562 and/or
1799945
Positive for P. aeruginosa 0.81 82 (Pratap et al., 2010)
FEV1% pred 0.03
FVC% pred 0.02
Annual change in FEV1% pred 0.003
Annual change in FVC% pred 0.001
HLA DRA 9268905 FEV1 % pred (adjusted) 1.42 × 10−5 1,978 (Wright et al., 2011) 557 (Wright et al., 2011)
DR4 Chronic P. aeruginosa colonization ≤0.03 98 (Aron et al., 1999) 72 (Laki et al., 2006)
DR7/DQA*0201 Chronic P. aeruginosa colonization <0.03
HMOX1 11354 A > G 2071749 FEV1 % pred 0.01 (0.29) 755 (Park et al., 2011)
4613 A > T 2071746 0.40 (0.03)
IFNG IFNγ +874 A > T Age of first P. aeruginosa infection No association 261 (Arkwright et al., 2003)
Age at which FEV1 < 50% 0.09
Age of death No association
IFRD1 57460 C > T 7817 Cross-sectional measures of lung function 0.004 (0.0168)£ 320 (Gu et al., 2009)
Longitudinal measures of lung function 0.016 (0.0187)£
FEV1% pred (adjusted) No association 1,978 (Wright et al., 2011)
47556 G > T 3807213 Longitudinal measures of lung function 0.080
38923 C > T 6968084 Cross-sectional measures of lung function 0.082
IL8 2227306 Pulmonary disease severity 0.19 737 385 (Hillian et al., 2008)
2227307 0.04 727
2227543 0.06 732 329 (Corvol et al., 2008)
−251 A > T 4073 0.07 733 (Hillian et al., 2008)
IL-10 −592 CC/- 1800872 Pulmonary function decline No association 261 (Arkwright et al., 2003)
−592 CC/TA Age of first P. aeruginosa or B. cepacia infection No association
Age of death No association
−1082 G > A 1800896 Colonization with A. fumigatus 0.06 (0.03)§ 0.02 (0.01)§ 378 (Brouard et al., 2005) 808 (Drumm et al., 2005)
Development of ABPA No association
Colonization with P. aeruginosa
KRT8/KRT18 1907671 Disease severity Associates 49 (24 sib pairs) (Stanke et al., 2011)
4300473 Associates
8608 Associates
7952 T > C 2035875 0.00131
1907671-4300473-
2035878-2035875
haplotype
Disease severity 0.0051
2638526 Disease severity NS
2070876 NS
KRT19 c.90T > C 11550883 Effective specific airway resistance 0.0093 95 (Gisler et al., 2012)
c.179G > C 4602 0.0052
11550883-4602
haplotype
0.0097
MASP-2 Exon 3 A > G,
D120G
72550870 Pulmonary function No association 112 (Carlsson et al., 2005) 109 (Olesen et al., 2006)
Need for transplantation No association
Colonization with P. aeruginosa 0.04
Lung function in patients colonized with S. aureus 0.04
MBL2 X1 – B (A > G)
X1 – C (A > G)
X1 – D (C > T)
(A/A, A/O, O/O)
−221 G > C (X/Y)
1800450
1800451
5030737
7096206
FEV1%
FVC%
Age of onset of P. aeruginosa
0.003
0.03
0.07
149 (Garred et al., 1999) 164 (Gabolde et al., 1999)
179 (Yarden et al., 2004)
298 (Davies et al., 2004)Θ
47 (Trevisiol et al., 2005)
135 (Choi et al., 2006)
254 (Buranawuti et al., 2007)
112 (Carlsson et al., 2005)
260 (Davies et al., 2004)Θ
47 (Trevisiol et al., 2005)
808 (Drumm et al., 2005)
105 (Faria et al., 2009)
788 (McDougal et al., 2010)
123 (Olesen et al., 2006)
Lung function No association 112 (Carlsson et al., 2005) 105 (Faria et al., 2009)
−550 G > C (H/L) Colonization No association
MIF −794 presence of absence of 5-CATT Colonization with P. aeruginosa 0.004 167 (Plant et al., 2005)
Colonization with S. aureus 0.50
Colonization with Candida 0.36
FEV1 ≥ 80% 0.14
NOS1 (AAT)9–15 Colonization with P. aeruginosa 0.0358 75 (Grasemann et al., 2000) 40 (Grasemann et al., 2002)
Mean FENO 0.027
(GT)18–36 Colonization with A. fumigatus 0.8505
0.025
59 (Texereau et al., 2004)
5 year decline of pulmonary function
NOS3 894 G > T FENO 0.07 (0.02 in females) 70 (Grasemann et al., 2003)
FEV1 0.08 (in females)
Colonization with P. aeruginosa <0.05
T5220G 1799983 Impairment of lung function (FEV1) 0.54 808 (Drumm et al., 2005)
PPP2R1A c.*465T > A 2162779 Functional residual capacity 0.0033 95 (Gisler et al., 2012)
PPP2R4 c.−185A > C 3118625 FEV1 0.0048 95 (Gisler et al., 2012)
Lung clearance index 0.0059
Effective specific airway resistance 0.0064
SCNN1B ENaCβ T313M
938 C > T
G589S
1765 G > A
Disease severity 56 (Viel et al., 2008)
SCNN1G ENaCγ L481G
1442 T > A
V546I
1636 G > A
5735–5723 haplotype Disease severity 56 (Viel et al., 2008)
SERPINA3 ACT, A1ACT T-15A 4934 FEV1% pred 0.04 157 (Mahadeva et al., 2001)
Radiography score 0.03
SFTPA1 6A3 (and 6A3/1A1 haplotype) FEV1% pred 0.01 135 (Choi et al., 2006)
DLCO 0.10
ATS score 0.006
AMA score 0.02
Dyspnea score 0.20
Physical score 0.002
Severity score 0.005
SFTPA2 1A1 (and 6A3/1A1 haplotype) FEV1% pred 0.009 135 (Choi et al., 2006)
DLCO 0.13
ATS score 0.007
AMA score 0.06
Dyspnea score 0.07
Physical score 0.12
Severity score 0.10
SLC8A3 12883884 FEV1% pred (adjusted) 1.20 × 10−6 1,978 (Wright et al., 2011) 557 (Wright et al., 2011)
SLC9A3 521096 C > T 4957061 Age of first P. aeruginosa infection 0.02 1,004
Decline of lung function (FEV1) 0.05 752 (Dorfman et al., 2011)
SNAP23 c.267-9T > C 9302112 FEF50 0.0088 95 (Gisler et al., 2012)
Functional residual capacity 0.011
Volume of trapped gas 0.0043
TGFB1 codon 10 C29T 1800470 Age at which FEV1 < 50% Age at which FVC < 70% <0.02
<0.005
171 (Arkwright et al., 2000)* 261 (Arkwright et al., 2003) 118 (Brazova et al., 2006) 1,978 (Wright et al., 2011)
codon 25 G74C 1800471 Age at which FEV1 < 50% Age at which FVC < 70% NS NS 808 (Drumm et al., 2005)*
C-509T 1800469 Impairment of lung function (FEV1) 0.006 808 (Drumm et al., 2005) 498 (Drumm et al., 2005)
329 (Corvol et al., 2008)
105 (Faria et al., 2009)
472 (Bremer et al., 2008)
254 (Buranawuti et al., 2007)
TLR4 D299G 4986790 Mean FEV1% pred 0.55 100 (Urquhart et al., 2006)
Mean FVC% pred 0.52
Age of first P. aeruginosa infection 0.78
Chrispin–Norman X-ray score 0.16
2688 G > A 10759931 Rate of change of FEV1% pred per year 0.12
FEV1 % pred 0.84 (0.55) 755 (Park et al., 2011)
TLR5 R392X 5744168 Mean FEV1 % pred 0.77 2219 (Blohmke et al., 2010)
TNFA TNFa G-308A (TNF2) 1800629 Mean FEV1% pred
Mean Chrispin–Norman X-ray score
0.02
0.17
53 (Hull and Thomson, 1998)
180 (Yarden et al., 2005)
261 (Arkwright et al., 2003)
180 (Yarden et al., 2005)
53 (Schmitt-Grohe et al., 2006)
Mean Shwachman score 0.17
No. positive for P. aeruginosa 0.72 808 (Drumm et al., 2005)
C-851T Mean FEV1% pred
Age of first P. aeruginosa infection
0.25
0.60
G-238A Mean FEV1% pred
Age of first P. aeruginosa infection
0.8
0.64
+691g ins/del Mean FEV1% pred
Age of first P. aeruginosa infection
0.008
0.018
TNFR1 TNFRSF1A intron 1 haplotype Disease severity Associates 37 sib pairs (Stanke et al., 2006)

§The number in parenthesis indicates the p-value for the association found in F508del homozygotes.

Inline graphicOnly multivariate p-values are reported. The number outside the parenthesis is the p-value for pediatrics and the number in parenthesis is the p-value for adults.

The association of missense variants with age at first P. aeruginosa-positive culture and age at onset of chronic P. aeruginosa was replicated in a population of only European American patients.

The association of missense variants with age at first P. aeruginosa-positive culture and age at onset of chronic P. aeruginosa was replicated in a population excluding patients with non-European ancestry.

+Found that only the c.−20G > A SNP associated with disease severity.

£The number in parenthesis indicates the p-value after a Bonferroni correction.

Found that −251 TT, +396TT, and +781CC may be associated with an earlier occurrence of chronic P. aeruginosa colonization, which is an indicator of disease severity, but this was not examined in the study by Hillian et al. (2008).

ΘThe association of MBL2 deficiency alleles with indicators of pulmonary disease severity was replicated in a population of 298 adults, but refuted in a population of 260 children.

Inline graphicThe Trevisiol et al. (2005) study replicated an association of MBL2 deficiency alleles with pulmonary function, but not with PA colonization.

*The study by Arkwright et al. (2000) found the severe variant at codon 10 to be T/T, but the study by Drumm et al. (2005) found the severe variant to be C/C at codon 10. A more detailed discussion of the TGB1 association with CF can be found in the text.

The vast majority of studies have been of the association design, predominantly due to the small number of families with multiple, affected children. These studies have evolved over time; cost and time restricted most early studies to screen for potential disease-modifying genes by candidate gene approaches with later studies utilizing array-based methods and soon whole-genome sequencing will be the state of the art. These three approaches are compared in Figure 2.

Figure 2.

Figure 2

Candidate gene approaches (A) have only involved a few variants in one to several dozen genes. Given a genome of roughly 25,000 genes, this represents a very small sampling (∼0.01% or less). GWAS (B) samples a much larger component of the genome, probing more than 90% of the genes, but it still only examines less than 5% of the over 50 million reference SNPs (http://www.ncbi.nlm.nih.gov/mailman/pipermail/dbsnp-announce/2012q2/000123.html) curated as of June, 2012. As costs come down, exome (not shown) and whole-genome sequencing (C) provide the potential to capture all variation in study subjects.

Phenotypic considerations

As lung disease is the major source of CF-related mortality, most studies have focused on some measure of lung function as a phenotype to examine for association. As most CF care centers carry out standard pulmonary function tests, spirometry has most commonly been used. Other tests may, in fact, be more specific for particular modifying functions, such as lung clearance index, but these are not as widely used and thus less practical for multi-center studies.

Candidate genes

Candidate genes are those suspected to have a role in some aspect of CF pathophysiology and variants in those genes are then tested for association with disease manifestations. Those traits may be represented by a continuum of values (lung disease severity, for example) or discrete traits, such as the occurrence of intestinal obstruction. Candidate gene selections for study involved many areas because of the complex pathophysiology of CF, including bacterial infections, inflammation, and lung remodeling/deterioration. This approach yielded multiple reports of putative modifiers of the CF pulmonary phenotype. For example, mannose-binding lectin (MBL), a gene involved in innate immunity, was one of the first potential modifier genes described. Low-expressing MBL alleles were found to associate with a more severe pulmonary disease course than those with higher expression (Garred et al., 1999). HLA haplotypes were also investigated as modifiers due to the role of the genes in this complex in innate defense and inflammation. Carriers of the HLA II DR7 haplotype were found to have a higher incidence of P. aeruginosa colonization (Aron et al., 1999).

Polymorphisms within cytokines and other inflammatory mediators were investigated as potential modifiers of CF pulmonary disease due to their role in immune response as well. Tumor necrosis factor alpha (TNFα) is a pro-inflammatory cytokine that is stimulated by NF-κB as a first line of defense against infection. The minor allele of a TNFα promoter polymorphism associated with worse pulmonary function in a small set of CF patients (Hull and Thomson, 1998). Interestingly, the TNFα minor allele that associated with a worse CF prognosis was also associated with an increase in mRNA expression level when measured using a reporter construct (Wilson et al., 1992). Interleukin-10 (IL-10), an anti-inflammatory cytokine was also investigated. Like TNFα, an IL-10 promoter polymorphism was also associated with differences in IL-10 expression (Turner et al., 1997). In this case, the lower expressing IL-10 allele was associated with worse CF disease. These studies supported a model in which higher levels of the pro-inflammatory cytokine TNFα, and lower levels of the anti-inflammatory cytokine IL-10 contribute to more severe CF lung disease.

Challenges of early candidate gene modifier studies

Early studies that attempted to identify potential modifiers were challenged by small numbers of study subjects. Typically, pulmonary function data using standard spirometry are not available on children younger than age 6, and multiple measures over time are needed to assess a subject’s trajectory, as an indicator of current and future disease severity. Nonetheless, numerous studies compared pulmonary function of subjects over a range of ages, statistically adjusting for age. Younger patients were included in order to maximize participation, but epidemiologic studies indicated that much of the pulmonary phenotypic variability was not present until after puberty (Zemel et al., 2000).

An additional constraint is that not all mutations in CFTR have the same consequences on protein function and thus it is likely to confound interpretation if CFTR genotype is not accounted for. Consequently, after limiting to patients with sufficient lung function measurements and comparable CFTR genotypes, the number of available subjects is low, making it unfeasible for any single center to carry out an association study that would have the statistical power to detect anything but a very major effect of a modifier gene.

Consortium approaches

The ability to effectively carry out genetic studies is limited by numbers of subjects. As a means to increase numbers, the European CF Twin and Sibling Study mentioned earlier was conceived and compared morphometric and pulmonary function indices of sib pairs. Using lung function measurements from patients in North America and Europe, this study was the first to compare lung function using a CF population for reference (Mekus et al., 2000).

Subsequently, the CF Gene Modifier Study (GMS) was conceived in 1999 to carry out a genetic study on a large group of patients for which longitudinal lung function data were available and genotype was restricted. In its inception, the study design was to use a candidate gene approach to search for potential genetic modifiers of CF pulmonary disease. The unique study design reduced genetic heterogeneity by using only patients who were homozygous for F508del (commonly referred to as ΔF508), and maximized the number of patients available by including patients from CF centers nationwide, comparing the most mild and most severe patients for differences in allele or genotype frequencies of single nucleotide polymorphisms (SNPs) or other gene-associated variants as markers of potential modifier genes.

Phenotypic categories of disease severity were defined using a patient’s forced expiratory volume in 1 s (FEV1), a pulmonary function index based on age, sex, and height, and used clinically to monitor CF disease progression and therapeutic efficacy. Subjects with FEV1 values in the upper quintile were classified as “mild” and those in the lower quintile as “severe.” Those subjects surviving beyond the age of 34 were classified as mild regardless of pulmonary function, as they represented the upper quintile of their birth cohort (Schluchter, 1992; Schluchter et al., 2002). DNA was obtained from these individuals and genotyped for a variety of variants in or near genes that were considered candidate modifiers.

In the initial candidate gene approach, 1,064 SNPs were tested in over 300 genes/gene regions that were chosen in the following ways: (1) they were SNPs that had previously been reported in the literature as associating with CF phenotype, (2) they were SNPs that were reportedly associated with similar pulmonary disease phenotypes, (3) they were genes that were known to play a key role in CF pathophysiology (Drumm et al., 2005).

Experience using this approach has shed light on the challenges involved in conducting modifier studies. Early studies struggled to achieve statistical power due to small sample sizes. Long and Langley (1999) calculated that the sample size must include at least 500 individuals in order to detect a causative polymorphism and for its association to be replicable. To accommodate the ability to replicate and maximize power, the GMS expanded to a North American Consortium that included a family-based genetic study at the Johns Hopkins University and a population-based study of Canadian CF patients being led by investigators at the University of Toronto and the Hospital for Sick Kids (Taylor et al., 2006). This consortium grew from the need to increase sample size and carry out replication studies and demonstrated its utility in a report that showed variants in the TGFB1 gene associate with pulmonary disease (Drumm et al., 2005) (discussed in more detail below).

The union of the three large studies provided a cohort of unprecedented size for studying modifiers of a single gene disorder, but also presented logistical issues due to the nature of the designs as each group had developed their own methods for assessing pulmonary phenotypes. Kulich et al. (2005) generated CF-specific reference equations for FEV1 that compare a CF subject’s lung function to CF subjects of the same age, sex, and height, as a more appropriate reference than the non-CF population and those values, adjusted for survival, were used to develop a phenotypic index that all three designs could incorporate.

The candidate gene approach showed the effectiveness of genetic studies, but a limitation is that it does not identify genetic locations other than those suspected to influence disease. That is, it will not detect modifying genes or pathways beyond those involved in our limited understanding of the disease. Understanding the functional effects of a modifier and its protein product fuel future studies to provide mechanistic insight of disease pathophysiology and how it might be dealt with (Cutting, 2010).

Associating Genes and Insight into their Modifying Mechanisms

One of the powerful attributes of genetics is that it allows one to identify clinically relevant genes, proteins, or pathways by virtue of the effect that variation in the gene produces on a clinical trait. However, the mechanisms by which genetic variation acts on the phenotype is not necessarily obvious. Thus, for any associating gene an obligatory step is to carry out functional studies to understand how it imparts its effect on disease presentation or outcome. Some examples are given below.

Associating genes: MBL

Mannose-binding lectin is a serum protein involved in innate immunity. MBL enhances phagocytosis of infectious organisms, especially during infancy, when adaptive immune response is immature (Eisen and Minchinton, 2003). Variant alleles that decrease MBL serum levels increase risk for many different infections (Garred et al., 1995, 1997; Summerfield et al., 1995, 1997) and have been shown to play a role in autoimmune diseases (Davies et al., 1995; Graudal et al., 1998). MBL has been suggested to regulate inflammatory responses, perhaps by delaying one of the first steps in inflammation or by reducing the levels of inflammatory cytokines (Jack et al., 2001). MBL is an attractive CF modifier candidate because it protects against infection and has some role in modulating inflammation.

Three amino acid substitutions in exon 1 (alleles B, C, and D) each contribute to decreased MBL plasma concentrations and are collectively referred to as 0, or null, alleles with the functional allele, containing none of the above variants, designated A. There are also variants with quantitative effects on mRNA expression, termed X, that also result in low MBL serum levels. Genotypes resulting in low MBL levels are designated low-producing or deficient alleles, but there are also genotype combinations associated with high and intermediate serum levels of MBL as well. Using the rationale that MBL protects against bacterial infection or somehow suppresses inflammation, then MBL deficiency alleles would be predicted to associate with a more severe CF lung disease.

In support of such a model, Garred et al. (1999) found that patients with higher expression MBL genotypes had a higher FEV1 and forced vital capacity (FVC). In other words, there was an additive effect of poor pulmonary function in the presence of an X allele. After further analysis, the cumulative adverse effects of low expression alleles were restricted to patients with chronic P. aeruginosa and were more pronounced in adults. MBL deficiency did not significantly associate with chronic colonization of P. aeruginosa. A study by Gabolde et al. found that cirrhosis of the liver was more common in CF patients carrying deficiency alleles, but other sources are conflicting about the association with CF liver disease (Gabolde et al., 2001; Bartlett et al., 2009; Tomaiuolo et al., 2009).

Several studies agree that MBL low expression alleles associate with lung function (Gabolde et al., 1999; Davies et al., 2004; Yarden et al., 2004; Trevisiol et al., 2005; Choi et al., 2006; Buranawuti et al., 2007; Dorfman et al., 2008), but there is no consensus as to whether this effect is only seen in patients colonized with P. aeruginosa, and whether a heterozygous genotype is sufficient to cause such impairment. Two studies found an association with chronic P. aeruginosa colonization (Trevisiol et al., 2005; McDougal et al., 2010), whereas others failed to detect an association between MBL alleles and colonization of any kind. Buranawuti et al. (2007) found that MBL high expression alleles predicted survival; the null genotype was underrepresented in adult populations and over represented in patients who died late in adolescence. This is consistent with multiple observations that the adverse effect of deficiency alleles is more pronounced in adults (Garred et al., 1999; Yarden et al., 2004; Buranawuti et al., 2007). In fact, a study by Davies et al. (2004) found no association between pulmonary function and MBL genotype in children. Despite replications, not all studies have detected associations between MBL alleles and lung disease severity (Carlsson et al., 2005; Drumm et al., 2005; Faria et al., 2009; McDougal et al., 2010).

Associating genes: TGFB1

As alluded to above, the first significant association identified by the consortium approach demonstrated that severity of pulmonary disease tracked with variants in the TGFB1 gene (Drumm et al., 2005). TGFB1 encodes transforming growth factor beta-1 (TGFβ1), a protein with complex function, involved in several cellular processes from differentiation and proliferation to innate immunity, and has been studied in relation to many disorders including Alzheimer’s disease, cancer, Marfan disease, and heart disease (Waltenberger et al., 1993; Yamamoto et al., 1993; Dickson et al., 2005; Brooke et al., 2008). Interest in investigating TGFβ1 as a potential modifier of CF pulmonary disease stemmed from both its biologic plausibility, and its identification as a modifier of asthma and chronic obstructive pulmonary disease (COPD) (Pulleyn et al., 2001; Celedon et al., 2004; Silverman et al., 2004; Wu et al., 2004).

TGFβ1 is biologically relevant to CF for several reasons. Leukocytes secrete TGFβ1 in response to infectious agents. TGFβ1 participates in the immune process by regulating the production of cytokines, and is generally thought to be pro-inflammatory in nature (Omer et al., 2003). TGFβ1 also increases the formation of extracellular tissue during injury repair by increasing production of connective tissue by altered gene regulation (Bartram and Speer, 2004). Post-injury repair in the lung is a delicate balance; inadequate remodeling leads to poor wound healing, whereas excessive remodeling leads to pathogenic fibrosis and scarring. There is strong evidence to suggest that the difference between these outcomes is at least in part related to TGFβ1 expression levels (Bartram and Speer, 2004).

Variation in TGFβ1 has been shown to modify asthma and COPD. A variant in the promoter region (C-509T), thought to be associated with increased TGFβ1 expression, was studied as a potential contributor to asthma disease severity. In two separate studies homozygosity for the T allele (associated with increased TGFβ1 production) was found to be more common among severe asthmatics when compared to mild asthmatics or healthy controls (Pulleyn et al., 2001; Silverman et al., 2004). Variation in codon 10 was studied in patients with COPD. In this case, the allele associated with increased TGFβ1 production was found more commonly in control patients, suggesting a protective role for TGFβ1 in COPD (Wu et al., 2004). Contrasting with associations found in asthma patients, the T allele of -509 was more prevalent in those with mild COPD (Celedon et al., 2004).

The TGFβ1 variants that have been implicated in other airway diseases have become a source of interest in CF as well. A study by Arkwright et al. (2000) found that the T allele (high producer genotype) in codon 10 associated with more rapid deterioration in lung function, while the genotype at codon 25 did not correlate with survival or lung function. Another study confirmed the codon 10 association found by Arkwright but interestingly, it was the C allele (low producer genotype) that prevailed in severe patients (Drumm et al., 2005). This finding, replicated in a second population of 498 patients, is counterintuitive given the protective role of TGFβ1 in COPD. The same study, by Drumm et al. found that the -509 T allele also associated with a severe pulmonary phenotype, which is the same adverse effect seen in asthma populations. There have been several attempts to resolve these conflicting data (Arkwright et al., 2000, 2003; Drumm et al., 2005; Brazova et al., 2006; Buranawuti et al., 2007; Bremer et al., 2008; Corvol et al., 2008; Faria et al., 2009), but only one study has used a relatively large cohort to accommodate the statistical power needed. It found that a haplotype of a 3′ C allele (rs8179181), -509 C, and codon 10 T associated with improved lung function to a greater degree than any SNP alone (Bremer et al., 2008). It would appear from these studies that CF more closely mimics the type of disease seen in asthma and that the same polymorphisms may be protective or adverse, depending on the genetic and environmental context.

Associating genes: IFRD1

Gu et al. (2009) applied a novel strategy by pooling equal amounts of DNA from similarly affected subjects into “mild” and “severe” pools and examined 320 patients in the GMS population (160 with severe lung disease, 160 with mild lung disease) with much lower cost and time than the other efforts. By quantifying the signal for each allele (rather than a yes/no output) the genotyping arrays were used to estimate allele frequencies in the pools. Discordant allele frequencies were identified between the pools using this strategy (Gu et al., 2009) and indicated that alleles of IFRD1 may contribute to pulmonary disease severity. In a subsequent study, however, IFRD1 variants did not significantly associate with lung disease (Wright et al., 2011).

The IFRD1 protein acts in a histone deacetylase (HDAC)-dependent manner to regulate gene expression (Vietor et al., 2002) and the IFRD1 gene is up-regulated during cell differentiation and regeneration in response to stress (Vietor and Huber, 2007). Previous studies found high expression in human blood cells (SymAtlas, 2008) and Gu et al. found highest expression in neutrophils, where up-regulation occurs during the final differentiation steps (Ehrnhoefer, 2009; Gu et al., 2009). The authors suggested that IFRD1 modulates CF lung disease through the regulation of neutrophil effector function, but that other explanations, involving different cell types, should not be ignored.

Genome-Wide Association Studies

Although the cost of large-scale genotyping had fallen more than a 1000-fold since these studies were initiated, genome sequencing was still well out of range by price and feasibility. Thus, it became feasible to think about whole genome, or genome-wide association studies (GWAS). A GWAS would rapidly interrogate hundreds of thousands of SNPs for association in large populations (Manolio, 2010) without bias imposed by pre-existing models and provide the opportunity to identify novel genes, regulatory loci, and pathways not previously considered. The disadvantage to testing so many variants is that there are statistical penalties that increase as the number of comparisons rises, and thus power is a major limitation (Cutting, 2010). This is less of a concern if the effect of a locus is large, but as common population variants are being examined in these studies, it is likely that the effects of any one locus are not large, perhaps with each accounting for only a few percent of the variation, for example (Long and Langley, 1999). It is an important concept to understand that these studies are conceptually analogous to those designed to find disease-causing genes, which would have major effects if they do, in fact, cause disease.

GWAS-identified associations

In a combined GWAS and family-based (linkage) study, 3,467 CF patients were tested for associations between lung disease severity and more than half a million SNPs (Wright et al., 2011). To accommodate the various study designs and data acquisition protocols, yet another method to examine pulmonary function, with age-specific CF percentile values of FEV1 (Kulich et al., 2005; Taylor et al., 2011), was developed and which accounted for mortality and longitudinal changes. With this phenotype and over 500,000 common genetic variants to assess for association, two new loci, one on chromosome 11p13 and one on chromosome 20q13 were identified as having variants that associate with lung function in CF.

The region on chromosome 11p13 of most significant association lies between two annotated genes, APIP and EHF. APIP encodes Apaf-1-interacting protein and EHF is a member of the epithelial-specific Ets transcription factors, both of which provide interesting candidates as disease modifiers, but through very different models, all of which must yet be worked out. It is important to understand that despite the power of genetics to identify such disease-relevant locations in the genome, it does not provide information regarding mechanisms and these must be examined empirically. APIP, for example, has been shown to suppress apoptosis in the presence of hypoxia (Cho et al., 2007), a context experienced by CF tissues. At this point, it is not clear if the adverse allele provides less or greater activity than the protective allele, but one could construct models either way. For example, one hypothesis is that excessive anti-apoptotic activity, resulting from increased APIP, could prolong neutrophilic inflammation and therefore lead to more severe lung disease (Wright et al., 2011). Similarly, EHF is reported to serve as a regulator of epithelial cell differentiation under conditions of stress and inflammation (Tugores et al., 2001; Wright et al., 2011) and thus could be modeled to have very important effects during airway development or remodeling from disease-related damage. Finally, it must be considered that the modifying locus could be working at a distance, involving a regulatory site such as a transcriptional enhancer or non-coding RNA.

The other associating region on chromosome 20 was detected by linkage analysis and then refined by association. The linkage signal includes several genes including MC3R, encoding the melanocortin-3 receptor, CBLN4 encoding cerebellin-like 4, CASS4, encoding Crk-associated substrate scaffolding (CASS) 4, and AURKA, encoding Aurora kinase A (Wright et al., 2011). With the exception of MC3R, which is a receptor involved in metabolic control, models to explain the other candidates are not presently clear.

Certainly functional studies will help sort out which genes in these associating intervals are responsible for their modifying effects, but these findings illustrate both the power and some of the challenges of genetic studies. On one hand, the unbiased approach provides the opportunity to identify novel disease modulators, but on the other hand identifying the source of the modifying effect and the mechanisms through with it acts are challenging tasks.

The Impact of Disease-Modifying Genes

The implications of disease-modifying genes are multiple. First, understanding the genetic contribution to phenotypic variation has the potential to provide insight into prognosis. Second, understanding the mechanisms by which these genes and their alleles are exerting their effects will likely suggest new therapeutic approaches or ways to optimize existing ones. Third, it opens the door to personalized medicine, as a given patient’s treatment regimen could conceivably be developed around a genetic profile. Using inflammation as an example, one could imagine a patient whose modifier panel predicts a lessened inflammatory response, and another patient whose modifier panel predicts a heightened inflammatory response. Inflammation is part of the immune response that is necessary to fight infection, however its prolonged state in CF patients can cause lung damage. The patient with the heightened response may benefit from anti-inflammatory drugs earlier, and the patient with the reduced inflammatory response may benefit from increased antibiotic usage. Both are common treatments for CF, but they may be used more beneficially with the help of modifier identification and mechanistic understanding.

Summary

Cystic fibrosis is a simple, Mendelian disorder with complex clinical manifestations that are consequences of CFTR genotype, environmental factors (Boyle, 2007), and heterogeneity throughout the entire genome. The discovery of genetic modifiers may help account for the broad spectrum of disease severity observed in patients, especially those with the same CFTR genotype. Modifying loci identified thus far each appear to contribute only a small percentage to overall disease profile and thus it is likely the combination of these variants in different permutations shape an individual’s outcome, an outcome that is also significantly influenced by non-genetic factors, as well as the interaction of genetic and non-genetic factors. There are few genes whose modifying effects withstand the test of replication and further studies must elucidate the role of each one in CF. Additional research about gene-environment interactions and gene–gene interactions will certainly demonstrate how complex these genetic effects are. With the careful use of candidate gene approaches and now, genome-wide scans (and soon whole-genome sequencing), it is realistic to believe that modifiers of CF disease will be identified and from which interventions tailored around an individual’s genetic profile will be developed. This fine-tuning of therapeutic strategies could contribute to better quality of life and ultimately, improved survival in CF.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Footnotes

References

  1. Allen J. R., McCauley J. C., Selby A. M., Waters D. L., Gruca M. A., Baur L. A., et al. (2003). Differences in resting energy expenditure between male and female children with cystic fibrosis. J. Pediatr. 142, 15–19 10.1067/mpd.2003.21 [DOI] [PubMed] [Google Scholar]
  2. Arkwright P. D., Laurie S., Super M., Pravica V., Schwarz M. J., Webb A. K., et al. (2000). TGF-beta(1) genotype and accelerated decline in lung function of patients with cystic fibrosis. Thorax 55, 459–462 10.1136/thorax.55.6.459 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Arkwright P. D., Pravica V., Geraghty P. J., Super M., Webb A. K., Schwarz M., et al. (2003). End-organ dysfunction in cystic fibrosis: association with angiotensin I converting enzyme and cytokine gene polymorphisms. Am. J. Respir. Crit. Care Med. 167, 384–389 10.1164/rccm.200204-364OC [DOI] [PubMed] [Google Scholar]
  4. Aron Y., Polla B. S., Bienvenu T., Dall’ava J., Dusser D., Hubert D. (1999). HLA class II polymorphism in cystic fibrosis. A possible modifier of pulmonary phenotype. Am. J. Respir. Crit. Care Med. 159, 1464–1468 10.1164/ajrccm.159.5.9807046 [DOI] [PubMed] [Google Scholar]
  5. Baranov V. S., Ivaschenko T., Bakay B., Aseev M., Belotserkovskaya R., Baranova H., et al. (1996). Proportion of the GSTM1 0/0 genotype in some Slavic populations and its correlation with cystic fibrosis and some multifactorial diseases. Hum. Genet. 97, 516–520 10.1007/BF02267078 [DOI] [PubMed] [Google Scholar]
  6. Barr H. L., Britton J., Smyth A. R., Fogarty A. W. (2011). Association between socioeconomic status, sex, and age at death from cystic fibrosis in England and Wales (1959 to 2008): cross sectional study. BMJ 343, d4662. 10.1136/bmj.d4662 [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bartlett J. R., Friedman K. J., Ling S. C., Pace R. G., Bell S. C., Bourke B., et al. (2009). Genetic modifiers of liver disease in cystic fibrosis. JAMA 302, 1076–1083 10.1001/jama.2009.1295 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bartram U., Speer C. P. (2004). The role of transforming growth factor beta in lung development and disease. Chest 125, 754–765 10.1378/chest.125.2.754 [DOI] [PubMed] [Google Scholar]
  9. Bear C. E., Li C. H., Kartner N., Bridges R. J., Jensen T. J., Ramjeesingh M., et al. (1992). Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell 68, 809–818 10.1016/0092-8674(92)90155-6 [DOI] [PubMed] [Google Scholar]
  10. Beucher J., Boelle P. Y., Busson P. F., Muselet-Charlier C., Clement A., Corvol H., et al. (2012). AGER-429T/C is associated with an increased lung disease severity in cystic fibrosis. PLoS ONE 7:e41913. 10.1371/journal.pone.0041913 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Blaisdell C. J., Howard T. D., Stern A., Bamford P., Bleecker E. R., Stine O. C. (2004). CLC-2 single nucleotide polymorphisms (SNPs) as potential modifiers of cystic fibrosis disease severity. BMC Med. Genet. 5:26. 10.1186/1471-2350-5-26 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Blohmke C. J., Park J., Hirschfeld A. F., Victor R. E., Schneiderman J., Stefanowicz D., et al. (2010). TLR5 as an anti-inflammatory target and modifier gene in cystic fibrosis. J. Immunol. 185, 7731–7738 10.4049/jimmunol.1001513 [DOI] [PubMed] [Google Scholar]
  13. Boyle M. P. (2007). Strategies for identifying modifier genes in cystic fibrosis. Proc. Am. Thorac. Soc. 4, 52–57 10.1513/pats.200605-129JG [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Brazova J., Sismova K., Vavrova V., Bartosova J., Macek M., Jr., Lauschman H., et al. (2006). Polymorphisms of TGF-beta1 in cystic fibrosis patients. Clin. Immunol. 121, 350–357 10.1016/j.clim.2006.08.015 [DOI] [PubMed] [Google Scholar]
  15. Bremer L. A., Blackman S. M., Vanscoy L. L., McDougal K. E., Bowers A., Naughton K. M., et al. (2008). Interaction between a novel TGFB1 haplotype and CFTR genotype is associated with improved lung function in cystic fibrosis. Hum. Mol. Genet. 17, 2228–2237 10.1093/hmg/ddn123 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Brooke B. S., Habashi J. P., Judge D. P., Patel N., Loeys B., Dietz H. C., III. (2008). Angiotensin II blockade and aortic-root dilation in Marfan’s syndrome. N. Engl. J. Med. 358, 2787–2795 10.1056/NEJMoa0706585 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Brouard J., Knauer N., Boelle P. Y., Corvol H., Henrion-Caude A., Flamant C., et al. (2005). Influence of interleukin-10 on Aspergillus fumigatus infection in patients with cystic fibrosis. J. Infect. Dis. 191, 1988–1991 10.1086/429964 [DOI] [PubMed] [Google Scholar]
  18. Buranawuti K., Boyle M. P., Cheng S., Steiner L. L., McDougal K., Fallin M. D., et al. (2007). Variants in mannose-binding lectin and tumour necrosis factor alpha affect survival in cystic fibrosis. J. Med. Genet. 44, 209–214 10.1136/jmg.2006.046318 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Buscher R., Eilmes K. J., Grasemann H., Torres B., Knauer N., Sroka K., et al. (2002). Beta2 adrenoceptor gene polymorphisms in cystic fibrosis lung disease. Pharmacogenetics 12, 347–353 10.1097/00008571-200207000-00002 [DOI] [PubMed] [Google Scholar]
  20. Carlsson M., Sjoholm A. G., Eriksson L., Thiel S., Jensenius J. C., Segelmark M., et al. (2005). Deficiency of the mannan-binding lectin pathway of complement and poor outcome in cystic fibrosis: bacterial colonization may be decisive for a relationship. Clin. Exp. Immunol. 139, 306–313 10.1111/j.1365-2249.2004.02690.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Celedon J. C., Lange C., Raby B. A., Litonjua A. A., Palmer L. J., DeMeo D. L., et al. (2004). The transforming growth factor-beta1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). Hum. Mol. Genet. 13, 1649–1656 10.1093/hmg/ddh171 [DOI] [PubMed] [Google Scholar]
  22. Cho D. H., Lee H. J., Kim H. J., Hong S. H., Pyo J. O., Cho C., et al. (2007). Suppression of hypoxic cell death by APIP-induced sustained activation of AKT and ERK1/2. Oncogene 26, 2809–2814 10.1038/sj.onc.1210080 [DOI] [PubMed] [Google Scholar]
  23. Choi E. H., Ehrmantraut M., Foster C. B., Moss J., Chanock S. J. (2006). Association of common haplotypes of surfactant protein A1 and A2 (SFTPA1 and SFTPA2) genes with severity of lung disease in cystic fibrosis. Pediatr. Pulmonol. 41, 255–262 10.1002/ppul.20361 [DOI] [PubMed] [Google Scholar]
  24. Corey M., Edwards L., Levison H., Knowles M. (1997). Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J. Pediatr. 131, 809–814 10.1016/S0022-3476(97)70025-8 [DOI] [PubMed] [Google Scholar]
  25. Corey M., Farewell V. (1996). Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am. J. Epidemiol. 143, 1007–1017 10.1093/oxfordjournals.aje.a008664 [DOI] [PubMed] [Google Scholar]
  26. Corvol H., Beucher J., Boelle P. Y., Busson P. F., Muselet-Charlier C., Clement A., et al. (2012). Ancestral haplotype 8.1 and lung disease severity in European cystic fibrosis patients. J. Cyst. Fibros. 11, 63–67 10.1016/j.jcf.2011.09.006 [DOI] [PubMed] [Google Scholar]
  27. Corvol H., Boelle P. Y., Brouard J., Knauer N., Chadelat K., Henrion-Caude A., et al. (2008). Genetic variations in inflammatory mediators influence lung disease progression in cystic fibrosis. Pediatr. Pulmonol. 43, 1224–1232 10.1002/ppul.20935 [DOI] [PubMed] [Google Scholar]
  28. Courtney J. M., Plant B. J., Morgan K., Rendall J., Gallagher C., Ennis M., et al. (2006). Association of improved pulmonary phenotype in Irish cystic fibrosis patients with a 3′ enhancer polymorphism in alpha-1-antitrypsin. Pediatr. Pulmonol. 41, 584–591 10.1002/ppul.20416 [DOI] [PubMed] [Google Scholar]
  29. Crovella S., Segat L., Amato A., Athanasakis E., Bezzerri V., Braggion C., et al. (2011). A polymorphism in the 5′ UTR of the DEFB1 gene is associated with the lung phenotype in F508del homozygous Italian cystic fibrosis patients. Clin. Chem. Lab. Med. 49, 49–54 10.1515/cclm.2011.023 [DOI] [PubMed] [Google Scholar]
  30. Cutting G. R. (2010). Modifier genes in Mendelian disorders: the example of cystic fibrosis. Ann. N. Y. Acad. Sci. 1214, 57–69 10.1111/j.1749-6632.2010.05879.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Cystic Fibrosis Foundation Patient Registry. (2009). 2008 Annual Data Report, Bethesda: Cystic Fibrosis Foundation. [Google Scholar]
  32. Darrah R., McKone E., O’Connor C., Rodgers C., Genatossio A., McNamara S., et al. (2010). EDNRA variants associate with smooth muscle mRNA levels, cell proliferation rates, and cystic fibrosis pulmonary disease severity. Physiol. Genomics 41, 71–77 10.1152/physiolgenomics.00185.2009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Davies E. J., Snowden N., Hillarby M. C., Carthy D., Grennan D. M., Thomson W., et al. (1995). Mannose-binding protein gene polymorphism in systemic lupus erythematosus. Arthritis Rheum. 38, 110–114 10.1002/art.1780380117 [DOI] [PubMed] [Google Scholar]
  34. Davies J. C., Turner M. W., Klein N. (2004). Impaired pulmonary status in cystic fibrosis adults with two mutated MBL-2 alleles. Eur. Respir. J. 24, 798–804 10.1183/09031936.04.00055404 [DOI] [PubMed] [Google Scholar]
  35. Davis P. B. (1999). The gender gap in cystic fibrosis survival. J. Gend. Specif. Med. 2, 47–51 [PubMed] [Google Scholar]
  36. Davis P. B., Drumm M., Konstan M. W. (1996). Cystic fibrosis. Am. J. Respir. Crit. Care Med. 154, 1229–1256 10.1164/ajrccm.154.5.8912731 [DOI] [PubMed] [Google Scholar]
  37. De Rose V., Arduino C., Cappello N., Piana R., Salmin P., Bardessono M., et al. (2005). Fcgamma receptor IIA genotype and susceptibility to P. aeruginosa infection in patients with cystic fibrosis. Eur. J. Hum. Genet. 13, 96–101 10.1038/sj.ejhg.5201285 [DOI] [PubMed] [Google Scholar]
  38. Demko C. A., Byard P. J., Davis P. B. (1995). Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J. Clin. Epidemiol. 48, 1041–1049 10.1016/0895-4356(94)00230-N [DOI] [PubMed] [Google Scholar]
  39. Di A., Brown M. E., Deriy L. V., Li C., Szeto F. L., Chen Y., et al. (2006). CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat. Cell Biol. 8, 933–944 10.1038/ncb1456 [DOI] [PubMed] [Google Scholar]
  40. Dickson M. R., Perry R. T., Wiener H., Go R. C. (2005). Association studies of transforming growth factor-beta 1 and Alzheimer’s disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 139B, 38–41 10.1002/ajmg.b.30218 [DOI] [PubMed] [Google Scholar]
  41. Divangahi M., Balghi H., Danialou G., Comtois A. S., Demoule A., Ernest S., et al. (2009). Lack of CFTR in skeletal muscle predisposes to muscle wasting and diaphragm muscle pump failure in cystic fibrosis mice. PLoS Genet. 5:e1000586. 10.1371/journal.pgen.1000586 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Dong Y. J., Chao A. C., Kouyama K., Hsu Y. P., Bocian R. C., Moss R. B., et al. (1995). Activation of CFTR chloride current by nitric oxide in human T lymphocytes. EMBO J. 14, 2700–2707 [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Dorfman R., Sandford A., Taylor C., Huang B., Frangolias D., Wang Y., et al. (2008). Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J. Clin. Invest. 118, 1040–1049 [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Dorfman R., Taylor C., Lin F., Sun L., Sandford A., Pare P., et al. (2011). Modulatory effect of the SLC9A3 gene on susceptibility to infections and pulmonary function in children with cystic fibrosis. Pediatr. Pulmonol. 46, 385–392 10.1002/ppul.21372 [DOI] [PubMed] [Google Scholar]
  45. Doring G., Krogh-Johansen H., Weidinger S., Hoiby N. (1994). Allotypes of alpha 1-antitrypsin in patients with cystic fibrosis, homozygous and heterozygous for deltaF508. Pediatr. Pulmonol. 18, 3–7 10.1002/ppul.1950180104 [DOI] [PubMed] [Google Scholar]
  46. Drumm M. L., Konstan M. W., Schluchter M. D., Handler A., Pace R., Zou F., et al. (2005). Genetic modifiers of lung disease in cystic fibrosis. N. Engl. J. Med. 353, 1443–1453 10.1056/NEJMoa051469 [DOI] [PubMed] [Google Scholar]
  47. Ehrnhoefer D. E. (2009). IFRD1 modulates disease severity in cystic fibrosis through the regulation of neutrophil effector function. Clin. Genet. 76, 148–149 10.1111/j.1399-0004.2009.01247_2.x [DOI] [PubMed] [Google Scholar]
  48. Eisen D. P., Minchinton R. M. (2003). Impact of mannose-binding lectin on susceptibility to infectious diseases. Clin. Infect. Dis. 37, 1496–1505 10.1086/379324 [DOI] [PubMed] [Google Scholar]
  49. Emond M. J., Louie T., Emerson J., Zhao W., Mathias R. A., Knowles M. R., et al. (2012). Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis. Nat. Genet. 44, 886–889 10.1038/ng.2344 [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Faria E. J., Faria I. C., Ribeiro J. D., Ribeiro A. F., Hessel G., Bertuzzo C. S. (2009). Association of MBL2, TGF-beta1 and CD14 gene polymorphisms with lung disease severity in cystic fibrosis. J. Bras. Pneumol. 35, 334–342 10.1590/S1806-37132009000400007 [DOI] [PubMed] [Google Scholar]
  51. Flamant C., Henrion-Caude A., Boelle P. Y., Bremont F., Brouard J., Delaisi B., et al. (2004). Glutathione-S-transferase M1, M3, P1 and T1 polymorphisms and severity of lung disease in children with cystic fibrosis. Pharmacogenetics 14, 295–301 10.1097/00008571-200405000-00004 [DOI] [PubMed] [Google Scholar]
  52. Fogarty A. W., Britton J., Clayton A., Smyth A. R. (2012). Are measures of body habitus associated with mortality in cystic fibrosis? Chest 142, 712–717 10.1378/chest.11-2124 [DOI] [PubMed] [Google Scholar]
  53. Frangolias D. D., Ruan J., Wilcox P. J., Davidson A. G., Wong L. T., Berthiaume Y., et al. (2003). Alpha 1-antitrypsin deficiency alleles in cystic fibrosis lung disease. Am. J. Respir. Cell Mol. Biol. 29, 390–396 10.1165/rcmb.2002-0271OC [DOI] [PubMed] [Google Scholar]
  54. Gabolde M., Guilloud-Bataille M., Feingold J., Besmond C. (1999). Association of variant alleles of mannose binding lectin with severity of pulmonary disease in cystic fibrosis: cohort study. BMJ 319, 1166–1167 10.1136/bmj.319.7218.1166a [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Gabolde M., Hubert D., Guilloud-Bataille M., Lenaerts C., Feingold J., Besmond C. (2001). The mannose binding lectin gene influences the severity of chronic liver disease in cystic fibrosis. J. Med. Genet. 38, 310–311 10.1136/jmg.38.5.310 [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Garred P., Madsen H. O., Balslev U., Hofmann B., Pedersen C., Gerstoft J., et al. (1997). Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet 349, 236–240 10.1016/S0140-6736(96)08440-1 [DOI] [PubMed] [Google Scholar]
  57. Garred P., Madsen H. O., Hofmann B., Svejgaard A. (1995). Increased frequency of homozygosity of abnormal mannan-binding-protein alleles in patients with suspected immunodeficiency. Lancet 346, 941–943 10.1016/S0140-6736(95)91559-1 [DOI] [PubMed] [Google Scholar]
  58. Garred P., Pressler T., Madsen H. O., Frederiksen B., Svejgaard A., Hoiby N., et al. (1999). Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J. Clin. Invest. 104, 431–437 10.1172/JCI6861 [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Gisler F. M., von Kanel T., Kraemer R., Schaller A., Gallati S. (2012). Identification of SNPs in the cystic fibrosis interactome influencing pulmonary progression in cystic fibrosis. Eur. J. Hum. Genet. 21, 397–403 10.1038/ejhg.2012.181 [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Grasemann H., Knauer N., Buscher R., Hubner K., Drazen J. M., Ratjen F. (2000). Airway nitric oxide levels in cystic fibrosis patients are related to a polymorphism in the neuronal nitric oxide synthase gene. Am. J. Respir. Crit. Care Med. 162, 2172–2176 10.1164/ajrccm.162.6.2003106 [DOI] [PubMed] [Google Scholar]
  61. Grasemann H., Storm van’s Gravesande K., Buscher R., Knauer N., Silverman E. S., Palmer L. J., et al. (2003). Endothelial nitric oxide synthase variants in cystic fibrosis lung disease. Am. J. Respir. Crit. Care Med. 167, 390–394 10.1164/rccm.200202-155OC [DOI] [PubMed] [Google Scholar]
  62. Grasemann H., Storm van’s Gravesande K., Gartig S., Kirsch M., Buscher R., Drazen J. M., et al. (2002). Nasal nitric oxide levels in cystic fibrosis patients are associated with a neuronal NO synthase (NOS1) gene polymorphism. Nitric Oxide 6, 236–241 10.1006/niox.2001.0408 [DOI] [PubMed] [Google Scholar]
  63. Graudal N. A., Homann C., Madsen H. O., Svejgaard A., Jurik A. G., Graudal H. K., et al. (1998). Mannan binding lectin in rheumatoid arthritis. A longitudinal study. J. Rheumatol. 25, 629–635 [PubMed] [Google Scholar]
  64. Gu Y., Harley I. T., Henderson L. B., Aronow B. J., Vietor I., Huber L. A., et al. (2009). Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease. Nature 458, 1039–1042 10.1038/nature07811 [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Henry M. T., Cave S., Rendall J., O’Connor C. M., Morgan K., FitzGerald M. X., et al. (2001). An alpha1-antitrypsin enhancer polymorphism is a genetic modifier of pulmonary outcome in cystic fibrosis. Eur. J. Hum. Genet. 9, 273–278 10.1038/sj.ejhg.5200623 [DOI] [PubMed] [Google Scholar]
  66. Hillian A. D., Londono D., Dunn J. M., Goddard K. A., Pace R. G., Knowles M. R., et al. (2008). Modulation of cystic fibrosis lung disease by variants in interleukin-8. Genes Immun. 9, 501–508 10.1038/gene.2008.42 [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Hollox E. J., Davies J., Griesenbach U., Burgess J., Alton E. W., Armour J. A. (2005). Beta-defensin genomic copy number is not a modifier locus for cystic fibrosis. J. Negat. Results Biomed. 4, 9. 10.1186/1477-5751-4-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Hull J., Thomson A. H. (1998). Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis. Thorax 53, 1018–1021 10.1136/thx.53.12.1018 [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Jack D. L., Read R. C., Tenner A. J., Frosch M., Turner M. W., Klein N. J. (2001). Mannose-binding lectin regulates the inflammatory response of human professional phagocytes to Neisseria meningitidis serogroup B. J. Infect. Dis. 184, 1152–1162 10.1086/323803 [DOI] [PubMed] [Google Scholar]
  70. Kerem E., Corey M., Kerem B. S., Rommens J., Markiewicz D., Levison H., et al. (1990a). The relation between genotype and phenotype in cystic fibrosis – analysis of the most common mutation (delta F508). N. Engl. J. Med. 323, 1517–1522 10.1056/NEJM199011293232203 [DOI] [PubMed] [Google Scholar]
  71. Kerem E., Corey M., Gold R., Levison H. (1990b). Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J. Pediatr. 116, 714–719 10.1016/S0022-3476(05)82653-8 [DOI] [PubMed] [Google Scholar]
  72. Korytina G. F., Iaibaeva D. G., Viktorova T. V. (2004). Polymorphism of glutathione-S-transferase M1 and P1 genes in patients with cystic fibrosis and chronic respiratory tract diseases. Genetika 40, 401–408 [PubMed] [Google Scholar]
  73. Krauss R. D., Berta G., Rado T. A., Bubien J. K. (1992). Antisense oligonucleotides to CFTR confer a cystic fibrosis phenotype on B lymphocytes. Am. J. Physiol. 263, C1147–C1151 [DOI] [PubMed] [Google Scholar]
  74. Kulich M., Rosenfeld M., Campbell J., Kronmal R., Gibson R. L., Goss C. H., et al. (2005). Disease-specific reference equations for lung function in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 172, 885–891 10.1164/rccm.200410-1335OC [DOI] [PubMed] [Google Scholar]
  75. Laki J., Laki I., Nemeth K., Ujhelyi R., Bede O., Endreffy E., et al. (2006). The 8.1 ancestral MHC haplotype is associated with delayed onset of colonization in cystic fibrosis. Int. Immunol. 18, 1585–1590 10.1093/intimm/dxl091 [DOI] [PubMed] [Google Scholar]
  76. Lamhonwah A. M., Bear C. E., Huan L. J., Kim Chiaw P., Ackerley C. A., Tein I. (2010). Cystic fibrosis transmembrane conductance regulator in human muscle: dysfunction causes abnormal metabolic recovery in exercise. Ann. Neurol. 67, 802–808 [DOI] [PubMed] [Google Scholar]
  77. Long A. D., Langley C. H. (1999). The power of association studies to detect the contribution of candidate genetic loci to variation in complex traits. Genome Res. 9, 720–731 [PMC free article] [PubMed] [Google Scholar]
  78. Mafficini A., Ortombina M., Sermet-Gaudelius I., Lebecque P., Leal T., Iansa P., et al. (2011). Impact of polymorphism of multidrug resistance-associated protein 1 (ABCC1) gene on the severity of cystic fibrosis. J. Cyst. Fibros. 10, 228–233 10.1016/j.jcf.2010.10.007 [DOI] [PubMed] [Google Scholar]
  79. Mahadeva R., Sharples L., Ross-Russell R. I., Webb A. K., Bilton D., Lomas D. A. (2001). Association of alpha(1)-antichymotrypsin deficiency with milder lung disease in patients with cystic fibrosis. Thorax 56, 53–58 10.1136/thorax.56.1.53 [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Mahadeva R., Westerbeek R. C., Perry D. J., Lovegrove J. U., Whitehouse D. B., Carroll N. R., et al. (1998a). Alpha1-antitrypsin deficiency alleles and the Taq-I G→A allele in cystic fibrosis lung disease. Eur. Respir. J. 11, 873–879 10.1183/09031936.98.11040873 [DOI] [PubMed] [Google Scholar]
  81. Mahadeva R., Stewart S., Bilton D., Lomas D. A. (1998b). Alpha-1 antitrypsin deficiency alleles and severe cystic fibrosis lung disease. Thorax 53, 1022–1024 10.1136/thx.53.6.501 [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Manolio T. A. (2010). Genomewide association studies and assessment of the risk of disease. N. Engl. J. Med. 363, 166–176 10.1056/NEJMra0905980 [DOI] [PubMed] [Google Scholar]
  83. McDonald T. V., Nghiem P. T., Gardner P., Martens C. L. (1992). Human lymphocytes transcribe the cystic fibrosis transmembrane conductance regulator gene and exhibit CF-defective cAMP-regulated chloride current. J. Biol. Chem. 267, 3242–3248 [PubMed] [Google Scholar]
  84. McDougal K. E., Green D. M., Vanscoy L. L., Fallin M. D., Grow M., Cheng S., et al. (2010). Use of a modeling framework to evaluate the effect of a modifier gene (MBL2) on variation in cystic fibrosis. Eur. J. Hum. Genet. 18, 680–684 10.1038/ejhg.2009.226 [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. McKone E. F., Shao J., Frangolias D. D., Keener C. L., Shephard C. A., Farin F. M., et al. (2006). Variants in the glutamate-cysteine-ligase gene are associated with cystic fibrosis lung disease. Am. J. Respir. Crit. Care Med. 174, 415–419 10.1164/rccm.200508-1281OC [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Mekus F., Ballmann M., Bronsveld I., Bijman J., Veeze H., Tummler B. (2000). Categories of deltaF508 homozygous cystic fibrosis twin and sibling pairs with distinct phenotypic characteristics. Twin Res. 3, 277–293 10.1375/136905200320565256 [DOI] [PubMed] [Google Scholar]
  87. Meyer P., Braun A., Roscher A. A. (2002). Analysis of the two common alpha-1-antitrypsin deficiency alleles PiMS and PiMZ as modifiers of Pseudomonas aeruginosa susceptibility in cystic fibrosis. Clin. Genet. 62, 325–327 10.1034/j.1399-0004.2002.620413.x [DOI] [PubMed] [Google Scholar]
  88. Milla C. E., Billings J., Moran A. (2005). Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis. Diabetes Care 28, 2141–2144 10.2337/diacare.28.9.2141 [DOI] [PubMed] [Google Scholar]
  89. Moss R. B., Hsu Y. P., Olds L. (2000). Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes. Clin. Exp. Immunol. 120, 518–525 10.1046/j.1365-2249.2000.01232.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. O’Connor G. T., Quinton H. B., Kneeland T., Kahn R., Lever T., Maddock J., et al. (2003). Median household income and mortality rate in cystic fibrosis. Pediatrics 111, e333–e339 10.1542/peds.111.2.e109 [DOI] [PubMed] [Google Scholar]
  91. Olesen H. V., Jensenius J. C., Steffensen R., Thiel S., Schiotz P. O. (2006). The mannan-binding lectin pathway and lung disease in cystic fibrosis – dysfunction of mannan-binding lectin-associated serine protease 2 (MASP-2) may be a major modifier. Clin. Immunol. 121, 324–331 10.1016/j.clim.2006.08.014 [DOI] [PubMed] [Google Scholar]
  92. Omer F. M., de Souza J. B., Riley E. M. (2003). Differential induction of TGF-beta regulates proinflammatory cytokine production and determines the outcome of lethal and nonlethal Plasmodium yoelii infections. J. Immunol. 171, 5430–5436 [DOI] [PubMed] [Google Scholar]
  93. Park J. E., Yung R., Stefanowicz D., Shumansky K., Akhabir L., Durie P. R., et al. (2011). Cystic fibrosis modifier genes related to Pseudomonas aeruginosa infection. Genes Immun. 12, 370–377 10.1038/gene.2011.5 [DOI] [PubMed] [Google Scholar]
  94. Plant B. J., Gallagher C. G., Bucala R., Baugh J. A., Chappell S., Morgan L., et al. (2005). Cystic fibrosis, disease severity, and a macrophage migration inhibitory factor polymorphism. Am. J. Respir. Crit. Care Med. 172, 1412–1415 10.1164/rccm.200412-1714OC [DOI] [PubMed] [Google Scholar]
  95. Pratap U., Quinn S., Blizzard L. B., Reid D. W. (2010). Population-based study of cystic fibrosis disease severity and haemochromatosis gene mutations. Respirology 15, 141–149 10.1111/j.1440-1843.2009.01649.x [DOI] [PubMed] [Google Scholar]
  96. Pulleyn L. J., Newton R., Adcock I. M., Barnes P. J. (2001). TGFbeta1 allele association with asthma severity. Hum. Genet. 109, 623–627 10.1007/s00439-001-0617-y [DOI] [PubMed] [Google Scholar]
  97. Reid D. W., Blizzard C. L., Shugg D. M., Flowers C., Cash C., Greville H. M. (2011). Changes in cystic fibrosis mortality in Australia, 1979-2005. Med. J. Aust. 195, 392–395 10.5694/mja10.11229 [DOI] [PubMed] [Google Scholar]
  98. Riordan J. R., Rommens J. M., Kerem B., Alon N., Rozmahel R., Grzelczak Z., et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245, 1066–1073 10.1126/science.2475911 [DOI] [PubMed] [Google Scholar]
  99. Robert R., Norez C., Becq F. (2005). Disruption of CFTR chloride channel alters mechanical properties and cAMP-dependent Cl-transport of mouse aortic smooth muscle cells. J. Physiol. (Lond.) 568, 483–495 10.1113/jphysiol.2005.085019 [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. Rodman D. M., Polis J. M., Heltshe S. L., Sontag M. K., Chacon C., Rodman R. V., et al. (2005). Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. Am. J. Respir. Crit. Care Med. 171, 621–626 10.1164/rccm.200403-404OC [DOI] [PubMed] [Google Scholar]
  101. Rommens J. M., Iannuzzi M. C., Kerem B., Drumm M. L., Melmer G., Dean M., et al. (1989). Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245, 1059–1065 10.1126/science.2772657 [DOI] [PubMed] [Google Scholar]
  102. Rubin B. K. (1990). Exposure of children with cystic fibrosis to environmental tobacco smoke. N. Engl. J. Med. 323, 782–788 10.1056/NEJM199009203231203 [DOI] [PubMed] [Google Scholar]
  103. Schechter M. S., Shelton B. J., Margolis P. A., Fitzsimmons S. C. (2001). The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States. Am. J. Respir. Crit. Care Med. 163, 1331–1337 10.1164/ajrccm.163.6.9912100 [DOI] [PubMed] [Google Scholar]
  104. Schluchter M. D. (1992). Methods for the analysis of informatively censored longitudinal data. Stat. Med. 11, 1861–1870 10.1002/sim.4780111408 [DOI] [PubMed] [Google Scholar]
  105. Schluchter M. D., Konstan M. W., Davis P. B. (2002). Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients. Stat. Med. 21, 1271–1287 10.1002/sim.1104 [DOI] [PubMed] [Google Scholar]
  106. Schmitt-Grohe S., Stuber F., Book M., Bargon J., Wagner T. O., Naujoks C., et al. (2006). TNF-alpha promoter polymorphism in relation to TNF-alpha production and clinical status in cystic fibrosis. Lung 184, 99–104 10.1007/s00408-005-2568-x [DOI] [PubMed] [Google Scholar]
  107. Segat L., Morgutti M., Athanasakis E., Trevisiol C., Amaddeo A., Poli F., et al. (2010). Analysis of DEFB1 regulatory SNPs in cystic fibrosis patients from North-Eastern Italy. Int. J. Immunogenet. 37, 169–175 10.1111/j.1744-313X.2010.00907.x [DOI] [PubMed] [Google Scholar]
  108. Silverman E. S., Palmer L. J., Subramaniam V., Hallock A., Mathew S., Vallone J., et al. (2004). Transforming growth factor-beta1 promoter polymorphism C-509T is associated with asthma. Am. J. Respir. Crit. Care Med. 169, 214–219 10.1164/rccm.200303-430CP [DOI] [PubMed] [Google Scholar]
  109. Stanke F., Becker T., Cuppens H., Kumar V., Cassiman J. J., Jansen S., et al. (2006). The TNFalpha receptor TNFRSF1A and genes encoding the amiloride-sensitive sodium channel ENaC as modulators in cystic fibrosis. Hum. Genet. 119, 331–343 10.1007/s00439-006-0140-2 [DOI] [PubMed] [Google Scholar]
  110. Stanke F., Becker T., Hedtfeld S., Tamm S., Wienker T. F., Tummler B. (2010). Hierarchical fine mapping of the cystic fibrosis modifier locus on 19q13 identifies an association with two elements near the genes CEACAM3 and CEACAM6. Hum. Genet. 127, 383–394 10.1007/s00439-009-0779-6 [DOI] [PubMed] [Google Scholar]
  111. Stanke F., Hedtfeld S., Becker T., Tummler B. (2011). An association study on contrasting cystic fibrosis endophenotypes recognizes KRT8 but not KRT18 as a modifier of cystic fibrosis disease severity and CFTR mediated residual chloride secretion. BMC Med. Genet. 12:62. 10.1186/1471-2156-12-62 [DOI] [PMC free article] [PubMed] [Google Scholar]
  112. Steinkamp G., von der Hardt H. (1994). Improvement of nutritional status and lung function after long-term nocturnal gastrostomy feedings in cystic fibrosis. J. Pediatr. 124, 244–249 10.1016/S0022-3476(94)70312-4 [DOI] [PubMed] [Google Scholar]
  113. Stern M., Wiedemann B., Wenzlaff P., German CysticFibrosis Quality and Assessment Group. (2008). From registry to quality management: the German cystic fibrosis quality assessment project 1995 2006. Eur. Respir. J. 31, 29–35 10.1183/09031936.00056507 [DOI] [PubMed] [Google Scholar]
  114. Stuhrmann M., Dork T., Krawczak M., Dueck M., Banholzer U., Domagk J., et al. (1991). Genotype-phenotype correlations in cystic fibrosis patients. Adv. Exp. Med. Biol. 290, 97–101; discussion 102–103. [DOI] [PubMed] [Google Scholar]
  115. Summerfield J. A., Ryder S., Sumiya M., Thursz M., Gorchein A., Monteil M. A., et al. (1995). Mannose binding protein gene mutations associated with unusual and severe infections in adults. Lancet 345, 886–889 10.1016/S0140-6736(95)90009-8 [DOI] [PubMed] [Google Scholar]
  116. Summerfield J. A., Sumiya M., Levin M., Turner M. W. (1997). Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series. BMJ 314, 1229–1232 10.1136/bmj.314.7089.1229 [DOI] [PMC free article] [PubMed] [Google Scholar]
  117. SymAtlas G. (2008). Available at: http://symatlas.gnf.org
  118. Taylor C., Commander C. W., Collaco J. M., Strug L. J., Li W., Wright F. A., et al. (2011). A novel lung disease phenotype adjusted for mortality attrition for cystic fibrosis genetic modifier studies. Pediatr. Pulmonol. 46, 857–869 10.1002/ppul.21456 [DOI] [PMC free article] [PubMed] [Google Scholar]
  119. Taylor C., Corey M., Breaton J., VanSpall M., Christofi M., Frangolias D., et al. (2006). The Canadian CF Modifier Gene Project: a nationally representative DNA and phenotype resource. Pediatr. Pulmonol. 41, 362. 10.1002/ppul.20451 [DOI] [Google Scholar]
  120. Taylor-Cousar J. L., Zariwala M. A., Burch L. H., Pace R. G., Drumm M. L., Calloway H., et al. (2009). Histo-blood group gene polymorphisms as potential genetic modifiers of infection and cystic fibrosis lung disease severity. PLoS ONE 4:e4270. 10.1371/journal.pone.0004270 [DOI] [PMC free article] [PubMed] [Google Scholar]
  121. Tesse R., Cardinale F., Santostasi T., Polizzi A., Manca A., Mappa L., et al. (2008). Association of beta-defensin-1 gene polymorphisms with Pseudomonas aeruginosa airway colonization in cystic fibrosis. Genes Immun. 9, 57–60 10.1038/sj.gene.6364440 [DOI] [PubMed] [Google Scholar]
  122. Texereau J., Marullo S., Hubert D., Coste J., Dusser D. J., Dall’Ava-Santucci J., et al. (2004). Nitric oxide synthase 1 as a potential modifier gene of decline in lung function in patients with cystic fibrosis. Thorax 59, 156–158 10.1136/thorax.2003.006718 [DOI] [PMC free article] [PubMed] [Google Scholar]
  123. The Cystic Fibrosis Genotype-Phenotype Consortium. (1993). Correlation between genotype and phenotype in patients with cystic fibrosis. N. Engl. J. Med. 329, 1308–1313 10.1056/NEJM199310283291804 [DOI] [PubMed] [Google Scholar]
  124. Tomaiuolo R., Degiorgio D., Coviello D. A., Baccarelli A., Elce A., Raia V., et al. (2009). An MBL2 haplotype and ABCB4 variants modulate the risk of liver disease in cystic fibrosis patients: a multicentre study. Dig. Liver Dis. 41, 817–822 10.1016/j.dld.2009.03.012 [DOI] [PubMed] [Google Scholar]
  125. Trevisiol C., Boniotto M., Giglio L., Poli F., Morgutti M., Crovella S. (2005). MBL2 polymorphisms screening in a regional Italian CF Center. J. Cyst. Fibros. 4, 189–191 10.1016/j.jcf.2005.04.001 [DOI] [PubMed] [Google Scholar]
  126. Tsui L. C., Durie P. (1997). Genotype and phenotype in cystic fibrosis. Hosp. Pract. (Off. Ed.) 32, 115–118 [DOI] [PubMed] [Google Scholar]
  127. Tugores A., Le J., Sorokina I., Snijders A. J., Duyao M., Reddy P. S., et al. (2001). The epithelium-specific ETS protein EHF/ESE-3 is a context-dependent transcriptional repressor downstream of MAPK signaling cascades. J. Biol. Chem. 276, 20397–20406 10.1074/jbc.M010930200 [DOI] [PubMed] [Google Scholar]
  128. Turner D. M., Williams D. M., Sankaran D., Lazarus M., Sinnott P. J., Hutchinson I. V. (1997). An investigation of polymorphism in the interleukin-10 gene promoter. Eur. J. Immunogenet. 24, 1–8 10.1111/j.1365-2370.1997.tb00001.x [DOI] [PubMed] [Google Scholar]
  129. Urquhart D. S., Allen J., Elrayess M., Fidler K., Klein N., Jaffe A. (2006). Modifier effect of the Toll-like receptor 4 D299G polymorphism in children with cystic fibrosis. Arch. Immunol. Ther. Exp. (Warsz.) 54, 271–276 10.1007/s00005-006-0029-8 [DOI] [PubMed] [Google Scholar]
  130. Vandebrouck C., Melin P., Norez C., Robert R., Guibert C., Mettey Y., et al. (2006). Evidence that CFTR is expressed in rat tracheal smooth muscle cells and contributes to bronchodilation. Respir. Res. 7, 113. 10.1186/1465-9921-7-113 [DOI] [PMC free article] [PubMed] [Google Scholar]
  131. Vankeerberghen A., Scudiero O., De Boeck K., Macek M., Jr., Pignatti P. F., Van Hul N., et al. (2005). Distribution of human beta-defensin polymorphisms in various control and cystic fibrosis populations. Genomics 85, 574–581 10.1016/j.ygeno.2005.02.003 [DOI] [PubMed] [Google Scholar]
  132. Vanscoy L. L., Blackman S. M., Collaco J. M., Bowers A., Lai T., Naughton K., et al. (2007). Heritability of lung disease severity in cystic fibrosis. Am. J. Respir. Crit. Care Med. 175, 1036–1043 10.1164/rccm.200608-1164OC [DOI] [PMC free article] [PubMed] [Google Scholar]
  133. Verma N., Bush A., Buchdahl R. (2005). Is there still a gender gap in cystic fibrosis? Chest 128, 2824–2834 10.1378/chest.128.4.2824 [DOI] [PubMed] [Google Scholar]
  134. Viel M., Leroy C., Hubert D., Fajac I., Bienvenu T. (2008). ENaCbeta and gamma genes as modifier genes in cystic fibrosis. J. Cyst. Fibros. 7, 23–29 10.1016/S1569-1993(08)60089-2 [DOI] [PubMed] [Google Scholar]
  135. Vietor I., Huber L. A. (2007). Role of TIS7 family of transcriptional regulators in differentiation and regeneration. Differentiation 75, 891–897 10.1111/j.1432-0436.2007.00205.x [DOI] [PubMed] [Google Scholar]
  136. Vietor I., Vadivelu S. K., Wick N., Hoffman R., Cotten M., Seiser C., et al. (2002). TIS7 interacts with the mammalian SIN3 histone deacetylase complex in epithelial cells. EMBO J. 21, 4621–4631 10.1093/emboj/cdf461 [DOI] [PMC free article] [PubMed] [Google Scholar]
  137. Waltenberger J., Lundin L., Oberg K., Wilander E., Miyazono K., Heldin C. H., et al. (1993). Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease. Am. J. Pathol. 142, 71–78 [PMC free article] [PubMed] [Google Scholar]
  138. Widerman E., Millner L., Sexauer W., Fiel S. (2000). Health status and sociodemographic characteristics of adults receiving a cystic fibrosis diagnosis after age 18 years. Chest 118, 427–433 10.1378/chest.118.2.427 [DOI] [PubMed] [Google Scholar]
  139. Wilson A. G., di Giovine F. S., Blakemore A. I., Duff G. W. (1992). Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Hum. Mol. Genet. 1, 353. 10.1093/hmg/1.5.353 [DOI] [PubMed] [Google Scholar]
  140. Wright F. A., Strug L. J., Doshi V. K., Commander C. W., Blackman S. M., Sun L., et al. (2011). Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat. Genet. 43, 539–546 10.1038/ng.838 [DOI] [PMC free article] [PubMed] [Google Scholar]
  141. Wu L., Chau J., Young R. P., Pokorny V., Mills G. D., Hopkins R., et al. (2004). Transforming growth factor-beta1 genotype and susceptibility to chronic obstructive pulmonary disease. Thorax 59, 126–129 10.1136/thorax.2003.005769 [DOI] [PMC free article] [PubMed] [Google Scholar]
  142. Yamamoto T., Nakamura T., Noble N. A., Ruoslahti E., Border W. A. (1993). Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc. Natl. Acad. Sci. U.S.A. 90, 1814–1818 10.1073/pnas.90.1.217 [DOI] [PMC free article] [PubMed] [Google Scholar]
  143. Yarden J., Radojkovic D., De Boeck K., Macek M., Jr., Zemkova D., Vavrova V., et al. (2004). Polymorphisms in the mannose binding lectin gene affect the cystic fibrosis pulmonary phenotype. J. Med. Genet. 41, 629–633 10.1136/jmg.2003.017947 [DOI] [PMC free article] [PubMed] [Google Scholar]
  144. Yarden J., Radojkovic D., De Boeck K., Macek M., Jr., Zemkova D., Vavrova V., et al. (2005). Association of tumour necrosis factor alpha variants with the CF pulmonary phenotype. Thorax 60, 320–325 10.1136/thx.2004.025262 [DOI] [PMC free article] [PubMed] [Google Scholar]
  145. Yoshimura K., Nakamura H., Trapnell B. C., Chu C. S., Dalemans W., Pavirani A., et al. (1991). Expression of the cystic fibrosis transmembrane conductance regulator gene in cells of non-epithelial origin. Nucleic Acids Res. 19, 5417–5423 10.1093/nar/19.19.5417 [DOI] [PMC free article] [PubMed] [Google Scholar]
  146. Zemel B. S., Jawad A. F., FitzSimmons S., Stallings V. A. (2000). Longitudinal relationship among growth, nutritional status, and pulmonary function in children with cystic fibrosis: analysis of the cystic fibrosis foundation national CF patient registry. J. Pediatr. 137, 374–380 10.1067/mpd.2000.107891 [DOI] [PubMed] [Google Scholar]
  147. Zielenski J. (2000). Genotype and phenotype in cystic fibrosis. Respiration 67, 117–133 10.1159/000029497 [DOI] [PubMed] [Google Scholar]
  148. Zielenski J., Corey M., Rozmahel R., Markiewicz D., Aznarez I., Casals T., et al. (1999). Detection of a cystic fibrosis modifier locus for meconium ileus on human chromosome 19q13. Nat. Genet. 22, 128–129 10.1038/9635 [DOI] [PubMed] [Google Scholar]

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES